Header Logo
Last Name

Dr Katharine Christine Carter

Title[no position]
Institution[no institution name]
Address[no address]
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Carter KC, Puig-Sellart M. Nanocarriers Made from Non-Ionic Surfactants or Natural Polymers for Pulmonary Drug Delivery. Curr Pharm Des. 2016; 22(22):3324-31. PMID: 27087597.
      View in: PubMed
    2. Siheri W, Igoli JO, Gray AI, Nasciemento TG, Zhang T, Fearnley J, Clements CJ, Carter KC, Carruthers J, Edrada-Ebel R, Watson DG. The isolation of antiprotozoal compounds from Libyan propolis. Phytother Res. 2014 Dec; 28(12):1756-60. PMID: 25044090.
      View in: PubMed
    3. Alawa JN, Carter KC, Nok AJ, Kwanashie HO, Adebisi SS, Alawa CB, Clements CJ. Infectivity of macrophages and the histopathology of cutaneous lesions, liver and spleen is attenuated by leaf extract of Vernonia amygdalina in Leishmania major infected BALB/c mice. J Complement Integr Med. 2012 Jun 18; 9:Article 10. PMID: 22713278.
      View in: PubMed
    4. Hendrickx S, Inocêncio da Luz RA, Bhandari V, Kuypers K, Shaw CD, Lonchamp J, Salotra P, Carter K, Sundar S, Rijal S, Dujardin JC, Cos P, Maes L. Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol. PLoS Negl Trop Dis. 2012; 6(5):e1664. PMID: 22666513; PMCID: PMC3362622.
    5. Italia JL, Sharp A, Carter KC, Warn P, Kumar MN. Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™. PLoS One. 2011; 6(10):e25744. PMID: 21998690; PMCID: PMC3188565.
    6. McFarlane E, Carter KC, McKenzie AN, Kaye PM, Brombacher F, Alexander J. Endogenous IL-13 plays a crucial role in liver granuloma maturation during Leishmania donovani infection, independent of IL-4Ra-responsive macrophages and neutrophils. J Infect Dis. 2011 Jul 01; 204(1):36-43. PMID: 21628656; PMCID: PMC3105032.
    7. Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine. 2009 Jun 02; 27(27):3643-9. PMID: 19464545.
      View in: PubMed
    8. Jones LA, Anthony JP, Henriquez FL, Lyons RE, Nickdel MB, Carter KC, Alexander J, Roberts CW. Toll-like receptor-4-mediated macrophage activation is differentially regulated by progesterone via the glucocorticoid and progesterone receptors. Immunology. 2008 Sep; 125(1):59-69. PMID: 18373668; PMCID: PMC2526260.
    9. Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, McFarlane E. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection. Vaccine. 2007 May 30; 25(22):4502-9. PMID: 17418459.
      View in: PubMed
    10. Qu X, Khutoryanskiy VV, Stewart A, Rahman S, Papahadjopoulos-Sternberg B, Dufes C, McCarthy D, Wilson CG, Lyons R, Carter KC, Schätzlein A, Uchegbu IF. Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude. Biomacromolecules. 2006 Dec; 7(12):3452-9. PMID: 17154474.
      View in: PubMed
    11. Clark RL, Carter KC, Mullen AB, Coxon GD, Owusu-Dapaah G, McFarlane E, Duong Thi MD, Grant MH, Tettey JN, Mackay SP. Identification of the benzodiazepines as a new class of antileishmanial agent. Bioorg Med Chem Lett. 2007 Feb 01; 17(3):624-7. PMID: 17113290.
      View in: PubMed
    12. Mullen AB, Lawrence CE, McFarlane E, Wei XQ, Carter KC. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate. Immunology. 2006 Nov; 119(3):348-54. PMID: 16879623; PMCID: PMC1819581.
    13. Mann JF, Scales HE, Shakir E, Alexander J, Carter KC, Mullen AB, Ferro VA. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods. 2006 Feb; 38(2):90-5. PMID: 16414269.
      View in: PubMed
    14. Carter KC, Hutchison S, Henriquez FL, Légaré D, Ouellette M, Roberts CW, Mullen AB. Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite gamma-glutamylcysteine synthetase. Antimicrob Agents Chemother. 2006 Jan; 50(1):88-95. PMID: 16377672; PMCID: PMC1346807.
    15. Carter KC, Hutchison S, Boitelle A, Murray HW, Sundar S, Mullen AB. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy. Parasitology. 2005 Dec; 131(Pt 6):747-57. PMID: 16336728.
      View in: PubMed
    16. Mann JF, Ferro VA, Mullen AB, Tetley L, Mullen M, Carter KC, Alexander J, Stimson WH. Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine. 2004 Jun 23; 22(19):2425-9. PMID: 15193405.
      View in: PubMed
    17. Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob Agents Chemother. 2003 May; 47(5):1529-35. PMID: 12709318; PMCID: PMC153333.
    18. Carter KC, Mullen AB, Sundar S, Kenney RT. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob Agents Chemother. 2001 Dec; 45(12):3555-9. PMID: 11709339; PMCID: PMC90868.
    19. Carter KC, Baillie AJ, Mullen AB. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection. Clin Diagn Lab Immunol. 1999 Jan; 6(1):61-5. PMID: 9874665; PMCID: PMC95661.
    20. Williams D, Mullen AB, Baillie AJ, Carter KC. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J Pharm Pharmacol. 1998 Dec; 50(12):1351-6. PMID: 10052848.
      View in: PubMed
    21. Mullen AB, Baillie AJ, Carter KC. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother. 1998 Oct; 42(10):2722-5. PMID: 9756784; PMCID: PMC105926.
    22. Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother. 1997 Oct; 41(10):2089-92. PMID: 9333030; PMCID: PMC164075.
    Carter's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description